Published in J Exp Med on June 01, 1983
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 3.22
Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 2.97
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci U S A (1993) 1.34
Immune recognition of self in immunity against cancer. J Clin Invest (2004) 1.27
Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice. Proc Natl Acad Sci U S A (1993) 1.22
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood (2013) 1.02
Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine. J Exp Med (1984) 0.94
Contributions of the T cell receptor-associated CD3gamma-ITAM to thymocyte selection. J Exp Med (2002) 0.90
Costimulatory signals are required for induction of transcription factor Nur77 during negative selection of CD4(+)CD8(+) thymocytes. Proc Natl Acad Sci U S A (1999) 0.85
Analysis of cellular mutants resistant to Theiler's virus infection: differential infection of L929 cells by persistent and neurovirulent strains. J Virol (1999) 0.83
The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines. Cancer Immun (2012) 0.78
Biologic therapy of cancer. Br J Cancer (1996) 0.75
Immunogenic capacity of tum--variants isolated from a rat rhabdomyosarcoma. Br J Cancer (1987) 0.75
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res (1960) 5.31
A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer (1976) 4.76
ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT. J Natl Cancer Inst (1964) 3.36
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med (1980) 1.91
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A (1977) 1.87
Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A (1977) 1.85
Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci U S A (1978) 1.63
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol (1982) 1.50
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med (1980) 1.44
Naturally arising tumors of the inbred WAB/Not rat strain. II. Immunogenicity of transplanted tumors. J Natl Cancer Inst (1981) 1.33
Immunologic approach to cancer. Transplant Proc (1970) 1.32
Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Proc Natl Acad Sci U S A (1979) 1.14
Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A (1982) 1.07
Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res (1983) 1.04
Stability of transplanted murine tumour systems after storage of cells at -196 degrees C for up to 13 years. Br J Cancer (1978) 0.86
Immunogenic variants obtained by mutagenesis of mouse Lewis lung carcinoma. Recognition of variant-specific antigens by cytolytic T lymphocytes. Eur J Cancer Clin Oncol (1982) 0.82
Viral xenogenization of intact tumor cells. Adv Cancer Res (1979) 0.81
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol (1985) 4.71
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol (1999) 3.76
Inactivation of ribosomes in vitro by colicin E 3 . Proc Natl Acad Sci U S A (1971) 3.53
[Teratocarcinoma of the mouse: isolation, culture and properties of pluripotential cells]. Ann Microbiol (Paris) (1973) 3.46
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 3.22
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity (1995) 3.13
An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res (2001) 3.08
A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med (1992) 2.92
Inactivation of ribosomes in vitro by colicin E 3 and its mechanism of action. Proc Natl Acad Sci U S A (1972) 2.88
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med (1995) 2.88
Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity (1997) 2.71
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 2.63
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics (1992) 2.45
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A (1989) 2.40
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci U S A (1988) 2.34
Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell (1989) 2.31
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 2.30
cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol (1988) 2.26
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 2.10
Purification and properties of colicin E3 immunity protein. J Biol Chem (1974) 1.92
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med (1980) 1.91
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med (1983) 1.89
Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A (1977) 1.85
T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis. Immunogenetics (1989) 1.84
Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer (1992) 1.83
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol (1994) 1.83
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
LAGE-1, a new gene with tumor specificity. Int J Cancer (1998) 1.76
Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell Mol Genet (1985) 1.76
DNA restriction and modification systems in Salmonella. I. SA and SB, two Salmonella typhimurium systems determined by genes with a chromosomal location comparable to that of the Escherichia coli hsd genes. Mol Gen Genet (1974) 1.68
DNA restriction and modification systems in Salmonella. SQ, a new system derived by recombination between the SB system of Salmonella typhimurium and the SP system of Salmonella potsdam. J Gen Microbiol (1976) 1.68
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res (1998) 1.66
Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci U S A (1978) 1.63
A mechanism for genetic recombination generating one parent and one recombinant. Proc Natl Acad Sci U S A (1969) 1.63
Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer (1994) 1.62
DNA restriction and modification systems in Salmonella. II. Genetic complementation between the K and B systems of Escherichia coli and the Salmonella typhimurium system SB, with the same chromosomal location. Mol Gen Genet (1974) 1.62
Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U S A (1994) 1.61
Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer (1992) 1.57
Host-controlled restriction mutants of Salmonella typhimurium. J Gen Microbiol (1969) 1.55
Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem (2000) 1.52
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol (1982) 1.50
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A (2001) 1.49
Chromosomal location of host specificity in Salmonella typhimurium. J Gen Microbiol (1970) 1.48
A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med (1997) 1.47
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med (1980) 1.44
PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol (1998) 1.43
The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol (1998) 1.43
Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol (1992) 1.42
A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med (1996) 1.42
Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med (1990) 1.41
Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer (2000) 1.39
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol (1995) 1.39
Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res (1999) 1.38
Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev (1995) 1.38
Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood (1999) 1.37
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol (1996) 1.34
High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res (2001) 1.26
Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol (1994) 1.24
Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics (1997) 1.23
Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer (1993) 1.22
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Eur J Immunol (1982) 1.22
Genotypes produced by individual recombination events involving bacteriophage f1. J Mol Biol (1971) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J (1990) 1.21
Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res (1983) 1.21
Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics (1987) 1.19
Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res (2000) 1.17
A new family of mouse genes homologous to the human MAGE genes. Genomics (1999) 1.17
MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer (2000) 1.17
The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. Int Immunol (1991) 1.16
Sequence and expression pattern of the human MAGE2 gene. Immunogenetics (1994) 1.16
Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression. Cold Spring Harb Symp Quant Biol (1989) 1.15